NEW YORK (GenomeWeb News) — Bio-Rad Laboratories today said third-quarter revenues increased 8 percent as R&D spending rose 8 percent and profit increased 43 percent.
 
Total receipts for the three months ended Sept. 30 increased to $305 million from $283 million year over year.
 
Revenue from the company’s Life Science division was up 4 percent to $137 million from $132 million while receipts from the Clinical Diagnostics segment jumped 11 percent to $164 million from $148 million year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.